Valuation Castle Biosciences, Inc.
Stocks
CSTL
US14843C1053
Medical Equipment, Supplies & Distribution
|
Market Closed -
Nasdaq
16:00:00 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 33.50 USD | -2.22% |
|
-2.05% | -13.88% |
| 08-27 | Castle Biosciences Insider Sold Shares Worth $317,112, According to a Recent SEC Filing | MT |
| 08-17 | Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas | MT |
Company Valuation: Castle Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,103 | 620.3 | 580.7 | 746.4 | 1,135 | 1,023 | - | - |
| Change | - | -43.76% | -6.38% | 28.53% | 52.12% | -9.87% | - | - |
| Enterprise Value (EV) | 773.4 | 361.7 | 337.6 | 746.4 | 1,135 | 1,023 | 1,023 | 1,023 |
| Change | - | -53.23% | -6.65% | 121.07% | 52.12% | -9.87% | 0% | 0% |
| P/E | -34.6x | -9.12x | -10.1x | 43x | -46.9x | -26.3x | -33.9x | -92.5x |
| PBR | 2.62x | 1.54x | 1.48x | 1.71x | 2.39x | 2.16x | 2.08x | - |
| PEG | - | -0x | 0.6x | -0x | 0x | -0.5x | 1.5x | 1.5x |
| Capitalization / Revenue | 11.7x | 4.53x | 2.64x | 2.25x | 3.3x | 2.74x | 2.5x | 2.22x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.74x | 2.5x | 2.22x |
| EV / EBITDA | -0x | -0x | -0x | 0x | 0x | 93.7x | 43.6x | 25.3x |
| EV / EBIT | -0x | -0x | -0x | 0x | -0x | -22x | -30.8x | -61.7x |
| EV / FCF | -0x | -0x | -0x | 0x | 0x | -47.6x | 76.7x | 35.2x |
| FCF Yield | -2.04% | -7.62% | -3.31% | 4.9% | 2.49% | -2.1% | 1.3% | 2.84% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.24 | -2.58 | -2.14 | 0.62 | -0.83 | -1.272 | -0.9889 | -0.362 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 94.08 | 137 | 219.8 | 332.1 | 344.2 | 372.9 | 409.4 | 461.4 |
| EBITDA 1 | -36.67 | -62.31 | -55.65 | 74.99 | 43.85 | 10.92 | 23.47 | 40.49 |
| EBIT 1 | -40.08 | -72.86 | -67.98 | 8.67 | -42.81 | -46.6 | -33.25 | -16.59 |
| Net income 1 | -31.29 | -67.14 | -57.47 | 18.24 | -24.16 | -38.03 | -27.75 | -6.773 |
| Net Debt | -329.6 | -258.6 | -243.1 | - | - | - | - | - |
| Reference price 2 | 42.87 | 23.54 | 21.58 | 26.65 | 38.90 | 33.50 | 33.50 | 33.50 |
| Nbr of stocks (in thousands) | 25,730 | 26,352 | 26,911 | 28,007 | 29,189 | 30,550 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/28/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -26.33x | - | - | - | 1.02B | |
| -50.29x | 16.41x | -120.35x | -.--% | 21.67B | |
| 18.42x | 2.05x | 8.66x | 1.39% | 10.28B | |
| -82.71x | 12.15x | -111.26x | -.--% | 8.02B | |
| 187.38x | 6.64x | 38.21x | -.--% | 7.24B | |
| 21.36x | 4.24x | 11.72x | - | 6.58B | |
| 22.07x | 7.66x | 17.19x | 2.61% | 6.09B | |
| 22.18x | 3.64x | 11.3x | 1.7% | 4.4B | |
| 17.46x | - | - | 3.51% | 2.81B | |
| Average | 14.40x | 7.54x | -20.65x | 1.32% | 7.57B | |
| Weighted average by Cap. | 2.76x | 9.53x | -45.16x | 0.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CSTL Stock
- Valuation Castle Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
